Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free cytk Stock Alerts $65.34 +0.54 (+0.83%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$64.50▼$66.1250-Day Range$63.75▼$80.9952-Week Range$25.98▼$110.25Volume628,014 shsAverage Volume2.90 million shsMarket Capitalization$6.83 billionP/E RatioN/ADividend YieldN/APrice Target$79.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside21.4% Upside$79.33 Price TargetShort InterestBearish13.91% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment-0.30Based on 7 Articles This WeekInsider TradingSelling Shares$9.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($3.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector290th out of 908 stocksPharmaceutical Preparations Industry128th out of 424 stocks 3.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.91% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Cytokinetics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 0.9 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cytokinetics this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,269,877.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($3.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesApril 26, 2024 | insidertrades.comJohn T. Henderson Sells 10,562 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 10, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $2,422,877.55 in StockApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 26, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson Sells 10,562 Shares of StockApril 24, 2024 | globenewswire.comCytokinetics to Announce First Quarter Results on May 8, 2024April 11, 2024 | uk.investing.comCytokinetics to present phase 3 trial results for heart drug at Heart Failure 2024April 11, 2024 | uk.investing.comCytokinetics EVP sells over $2.4m in company stockApril 10, 2024 | globenewswire.comCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 10, 2024 | globenewswire.comCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 9, 2024 | finance.yahoo.comEVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Strong Aficamten Trial ResultsApril 5, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cytokinetics Amid Promising Aficamten Clinical ResultsApril 5, 2024 | globenewswire.comCytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific SessionApril 3, 2024 | benzinga.com$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much TodayApril 2, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | globenewswire.comCytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | seekingalpha.comCytokinetics, Incorporated: Buyout Speculation PersistsMarch 30, 2024 | finance.yahoo.comCYTK Apr 2024 60.000 callMarch 27, 2024 | msn.comCytokinetics gains amid renewed takeover speculationMarch 25, 2024 | globenewswire.comCytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific SessionMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comCYTK Mar 2024 63.000 callMarch 15, 2024 | finance.yahoo.comCYTK Mar 2024 69.000 putMarch 15, 2024 | finance.yahoo.comCYTK Mar 2024 69.000 callMarch 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)March 15, 2024 | finance.yahoo.comCYTK Mar 2024 62.000 callSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/26/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$79.33 High Stock Price Target$108.00 Low Stock Price Target$50.00 Potential Upside/Downside+21.4%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-6,988.63% Pretax Margin-6,988.63% Return on EquityN/A Return on Assets-65.08% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales907.47 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-16.58Miscellaneous Outstanding Shares104,580,000Free Float101,020,000Market Cap$6.83 billion OptionableOptionable Beta0.68 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President & Director Comp: $1.14MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $463.75kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $776.99kMr. Andrew M. Callos (Age 68)Executive VP & Chief Commercial Officer Comp: $745.4kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Dr. Stuart Kupfer M.D.Senior VP & Chief Medical OfficerMr. Eric TerhaerdtSenior Vice President of Development OperationsMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANViking TherapeuticsNASDAQ:VKTXIntra-Cellular TherapiesNASDAQ:ITCIIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsPeregrine Capital Management LLCSold 5,121 shares on 4/26/2024Ownership: 0.121%Yousif Capital Management LLCSold 3,496 shares on 4/26/2024Ownership: 0.043%New York State Teachers Retirement SystemSold 18,065 shares on 4/25/2024Ownership: 0.109%WCM Investment Management LLCBought 43,866 shares on 4/25/2024Ownership: 0.042%John T HendersonSold 10,562 sharesTotal: $681,671.48 ($64.54/share)View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 brokers have issued 1 year target prices for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $108.00. On average, they predict the company's stock price to reach $79.33 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 on January 1st, 2024. Since then, CYTK stock has decreased by 21.7% and is now trading at $65.34. View the best growth stocks for 2024 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest in April. As of April 15th, there was short interest totaling 14,040,000 shares, an increase of 6.1% from the March 31st total of 13,230,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is currently 6.9 days. Currently, 13.9% of the shares of the company are sold short. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CYTK earnings forecast. How can I listen to Cytokinetics' earnings call? Cytokinetics will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to analysts' expectations of $7.62 million. The business's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.45) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.12%), New York State Teachers Retirement System (0.11%), Amalgamated Bank (0.05%), Yousif Capital Management LLC (0.04%), WCM Investment Management LLC (0.04%) and Mirador Capital Partners LP (0.03%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.